FMP

FMP

Enter

TWST - Twist Bioscience Cor...

photo-url-https://images.financialmodelingprep.com/symbol/TWST.png

Twist Bioscience Corporation

TWST

NASDAQ

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

50.66 USD

3.1 (6.12%)

Latest TWST News

InvestorPlace

Aug 7, 2024

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.

Read More

Parth Sanghvi

Aug 6, 2024

Twist Bioscience Reports Robust Q3 Growth and Targets Higher Margins: Key Insights from the Earnings Call

Twist Bioscience Reports Robust Q3 Growth and Targets Higher Margins: Key Insights from the Earnings Call Twist Bioscience has recently shared its Q3 earnings report, highlighting impressive growth and ambitious plans for increasing profit margins. The company’s earnings call provided valuable details on its performance, strategic goals, and future outlook. Here’s a comprehensive overview of Twist Bioscience’s recent achievements and strategic focus. Highlights from Twist Bioscience’s Q3 E...

Read More

InvestorPlace

Aug 5, 2024

The 3 Best Med Tech Stocks to Buy Now

According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.

Read More

Seeking Alpha

Aug 4, 2024

Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)

Twist Bioscience reported revenue of $81.5 million in Q2 (fiscal Q3), marking a 28% increase from Q2, 2023. Twist's biopharma segment underperformed, contributing to a significant impairment charge. The company's future relies on its synthetic biology segment, facing competition and uncertain prospects in a rapidly evolving market.

Read More

Seeking Alpha

Aug 2, 2024

Twist Bioscience Corporation (TWST) Q3 2024 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST ) Q3 2024 Earnings Conference Call August 2, 2024 8:00 AM ET Company Participants Angela Bitting - Senior Vice President, Corporate Affairs Emily Leproust - Chief Executive Officer & Co-Founder Adam Laponis - Chief Financial Officer Patrick Finn - President and COO Conference Call Participants Steven Mah - Cowen Matt Larew - William Blair Luke Sergott - Barclays Vijay Kumar - Evercore ISI Sung-Ji Nam - Scotiabank Subbu Nambi - Guggenheim Securities Punee...

Read More

Zacks Investment Research

Aug 2, 2024

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $1.01 per share a year ago.

Read More

Zacks Investment Research

Jul 30, 2024

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Read More

Zacks Investment Research

Jul 26, 2024

Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More

Zacks Investment Research

Jul 22, 2024

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Read More

Zacks Investment Research

May 22, 2024

What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?

Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read More
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep